Sector News

U.K.’s Brexit skeptic defying biopharma deal splash fizzles

December 6, 2017
Life sciences

The United Kingdom government has unveiled its highly anticipated deal with the life sciences sector. As previously leaked, the document (PDF) details planned investments from drug developers including GlaxoSmithKline, although many of the commitments are vague or already known.

GSK is committing £40 million ($53 million) to expand the genome sequencing program it created with Regeneron and UK Biobank earlier this year. In March, GSK and Regeneron put up an “initial investment” to sequence the first 50,000 of a planned 500,000 genomes. The £40 million is the anticipated follow-up investment that will fund sequencing of all participants, an expansion that GSK made sound like a sure thing in March.

The GSK investment, while expected, is a rare example of a new number in the report. Many of the other projects trumpeted in the report are either already well known or vague and of questionable significance for the U.K. life sciences sector.

Novo Nordisk’s £115 million research center in Oxford falls into the former camp. A collaboration between Johnson & Johnson and the University of Oxford on clinical trial methodologies falls into the latter.

The biggest disconnect between leaked news reports and reality relates to the VC investment and relocation story broken by the Sunday Times and Financial Times over the weekend. Those articles described the investment of up to $1 billion by a U.S. life sciences fund that planned to relocate a “significant” portion of its operations to the U.K.

No such actions are described in the report. The only news in the same ballpark is that Apple Tree Partners “has signalled its intention to create a biopharmaceutical company in the U.K.” Apple Tree is the VC shop behind biotechs including Gloucester Pharmaceuticals, which Celgene gobbled up in 2009 for $340 million upfront and a similar amount in milestones.

Apple Tree’s involvement in the creation of a U.K. biotech would be a welcome development for the country. But the news and the rest of the report—which retreads ground about how the U.K. will help the industry—aren’t the sort of narrative-shifting events the government needs to reassure businesses about the post-Brexit future of the country.

Given events elsewhere this week, it is questionable whether any sector deal could have captured much of the news agenda. The report was released against a backdrop of deepening strife in the Brexit negotiations and the revelations that the government hasn’t assessed the possible effects of leaving the European Union on any industries.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).